Amgen speaks out about bone density concerns with obesity drug
14 hours ago · AMGN. Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe. The company has tried to ...
Amgen Suffers Surprise Blow as New Bone Density Safety
1 day ago · Amgen lost more than 7% of its value in trading on Tuesday after reports circulated that its highly anticipated obesity candidate MariTide could have negative effects on bone mineral density, raising concerns that the investigational therapy could aggravate the risk of fractures in patients. The bone marrow density (BMD) data were first spotted ...
Amgen dismisses bone density concerns related to its weight-loss …
1 day ago · The drugmaker's stock slumped 7% on Tuesday after analysts at Cantor Fitzgerald said their review of early-stage data on Amgen's MariTide showed a drop in bone mineral density, which can increase ...
Amgen Shrugs Off Bone Density Concerns Related to Obesity …
7 hours ago · Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
1 day ago · The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data later this year."
Amgen Defends Its Investigational Monthly Weight Loss Injection …
1 day ago · Analysts referred to new public data from a phase one study, showing that the highest dose of MariTide (420 milligrams) was associated with around 4% decrease in bone mineral density over 12 weeks.
Amgen MariTide bone mineral density loss data ‘leaked,’ says …
3 days ago · Nov. 12, 2024, 01:30 PM. Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file seems to show bone mineral density, or BMD ...
A scrap of data on Amgen's obesity drug MariTide wipes out …
2 days ago · Nov. 12, 2024. National Biotech Reporter. On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, spotted by an ...
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
1 day ago · "As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern ...
Amgen Defends Its Investigational Monthly Weight Loss
2 days ago · Analysts referred to new public data from a phase one study, showing that the highest dose of MariTide (420 milligrams) was associated with around 4% decrease in bone mineral density over 12 weeks.
- Some results have been removed